Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis

Not Applicable

Recruiting

• Conditions: Transcatheter Aortic Valve Implantation

• Registration Number: NCT05804903
• Lead Sponsor: NVT GmbH

Brief Summary

The EMPIRE II study evaluates the safety and performance of the entire ALLEGRA THV System.

The primary safety endpoint is composite of all-cause mortality or stroke rates at 12 months. And the primary performance endpoint is device success at 7 days.

Based on the outcomes of a study with a similar device and considering a drop-out rate of 5%, 177 patients need to be enrolled in the study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-03-14
• Study First Submitted QC: 2023-03-27
• Study First Posted: 2023-04-07
• Study Start: 2023-11-24
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-21
• Last Update Posted: 2024-02-23
• Primary Completion: 2025-03-01
• Study Completion: 2029-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 177

Inclusion Criteria

1. Symptomatic severe calcific stenosis of a native aortic valve with an AVA ≤1.0 cm2 (or AVA index ≤0.6 cm2/m2), AND mean aortic pressure gradient ≥ 40mmHg OR maximal transaortic velocity ≥4.0m/s OR Doppler velocity index ≤0.25 on site-reported echocardiography OR symptomatic patients with degeneration of a surgical bioprosthetic valve (stenosis +/- insufficiency) on site-reported echocardiography
2. Local multi-disciplinary Heart Team and Central Screening Committee (CSC) agree on indication and eligibility for TAVI
3. Age ≥18 years
4. Patient has signed the Patient Informed Consent Form
5. Patient is willing and able to comply with requirements of the study, including all follow-up visits

Exclusion Criteria

Patient will not be included if ANY one of the following conditions exists:

General:

1. Mean aortic annulus diameter as measured by pre-procedural CT or internal diameter of the bioprosthesis is <16.5 mm or >27 mm

2. Echocardiographic evidence of intracardiac thrombus or vegetation (site-reported)

3. Significant disease of the aorta that would preclude safe advancement of the ALLEGRA Plus THV System

4. Severe ilio-femoral vessel disease that would preclude safe placement of an 18 Fr introducer sheath or make endovascular access impossible

5. Porcelain aorta

6. Severe left ventricular dysfunction with ejection fraction (EF) <20% (site-reported)

7. Evidence of active endocarditis or other acute infections

8. Renal failure requiring continuous renal replacement therapy

9. Untreated clinically significant coronary artery disease requiring revascularization

10. Any percutaneous interventional procedure (e.g. PCI with stenting) within 14 days prior of the index procedure

11. Acute MI ≤30 days prior to the index procedure

12. Symptomatic carotid or vertebral artery disease requiring intervention or carotid/vertebral intervention within the preceding 45 days

13. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) ≤6 months or prior CVA with moderate or severe disability (e.g. modified Rankin scale score >2)

14. History of bleeding diathesis or coagulopathy; acute blood dyscrasias as defined: thrombocytopenia (platelets <80,000/µl), acute anemia (hemoglobin <10 g/dl), leukopenia (WBC <3000/ µl)

15. Active peptic ulcer or gastrointestinal (GI) bleeding ≤3 months

16. Severe (greater than 3+) mitral insufficiency (site-reported)

17. Uncontrolled atrial fibrillation

18. Required emergency surgery for any reason

19. Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or contraindication to anticoagulant or anti-platelet medication or to nitinol alloy or to bovine tissue

20. Life expectancy ≤12 months due to other medical illness

21. Currently participating in another investigational drug or device study

22. Hypertrophic obstructive cardiomyopathy

23. Pregnancy or intend to become pregnant during study participation

    Specific exclusions in patients with native aortic valve disease (site-reported):

24. Unicuspid or bicuspid aortic valve

25. Non-calcified aortic stenosis

26. Identified risk of coronary occlusion due to Sinus of Valsalva anatomy and/or bulky calcified aortic valve leaflets in close proximity to coronary ostia

    Specific exclusions in patients with degenerated surgical bioprosthetic aortic valves (valve-in-valve) (site-reported):

27. High risk of coronary occlusion

28. Partially detached leaflets that may obstruct a coronary ostium

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Composite of all-cause mortality or stroke rates	12 months

Secondary Outcome Measures

Name	Time	Method
NYHA classification	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Cardiovascular mortality rate	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Any stroke rate	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
All-cause mortality rate	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Device success rate	30 days	Device success at 30 days (In-hospital may be used if 30-day data are not available): * Technical success; * Freedom from mortality; * Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access-related or cardiac structural complication; * Intended performance of the valve‡(mean gradient\<20 mmHg, peakvelocity\<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation
Effective orifice area (EOA) as assessed by transthoracic echocardiogram (TTE)	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years	as determined by an independent Echo Core Lab
Transvalvular mean and peak pressure gradient as assessed by transthoracic echocardiogram (TTE)	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years	as determined by an independent Echo Core Lab
New pacemaker implantation rate	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Life-threatening/major bleeding (BARC 3b or more)	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Transient ischemic attack rate	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Major vascular complications according to VARC-3	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years
Early safety profile according to VARC-3	30 days
Quality of life as assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years	Assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Patients are asked questions about physical limitation, symptom frequency, quality of life, and social limitation. Responses are given on a Likert scale that for each individual item is scored on a scale of 0-100 with higher scores indicating better health.
Transvalvular mean and peak pressure gradient as assessed by transthoracic	7 days, 30 days, 6 months, 12 months, 2 years, 3 years , 4 years, 5 years	as determined by an independent Echo Core Lab

Trial Locations

Locations (7)

Oulu University Hospital; 🇫🇮 Oulu, Finland

Deutsches Herzzentrum Berlin; 🇩🇪 Berlin, Germany

Klinika Kardiochirurgii; 🇵🇱 Gdańsk, Poland

III Katedra Kardiologii; 🇵🇱 Katowice, Poland

Reina Sofia Hospital; 🇪🇸 Córdoba, Spain

Hospital La Paz; 🇪🇸 Madrid, Spain

Herzzentrum - Luzerner Kantonsspital; 🇨🇭 Luzern, Switzerland